Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Receptos Inc Files Registration Statement For Initial Public Offering To Raise Up To USD86.3 Million-GlobalData Financial Deals Tracker


Wednesday, 8 May 2013 08:00pm EDT 

GlobalData Financial Deals Tracker reported that Receptos Inc has filed a registration statement with the US Securities and Exchange Commission (SEC) for initial public offering (IPO) of shares of its common stock to raise gross proceeds of up to USD86.3 million. The Company intends to apply for listing its common stock on the NASDAQ Global Market, under the symbol RCPT. The Company intends to use the net proceeds to fund the Phase II portion of accelerated design, randomized Phase II/III study of RPC1063 in patients with RMS (relapsing multiple sclerosis); fund randomized Phase II study of RPC1063 in patients with UC (ulcerative colitis); fund the initiation of the Phase III portion of accelerated design, randomized Phase II/III study of RPC1063 in patients with RMS; fund the initiation of randomized Phase II study of RPC4046 in patients with EoE (eosinophilic esophagitis); and for in-house research activities, working capital and general corporate purposes. Credit Suisse Securities (USA) LLC, Leerink Swann LLC and BMO Capital Markets Corp. are acting as joint book-running managers; Wedbush PacGrow Life Sciences is acting as a co-manager; and Pillsbury Winthrop Shaw Pittman LLP is acting as legal advisor to the Company for the offering. 

Company Quote

38.23
-0.8 -2.05%
24 Jul 2014